Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
By Sydney Price · May 13, 2024, 10:18 PM EDT
A proposed class of Biogen shareholders urged a Massachusetts federal court to certify their now-revived class action alleging the drugmaker made misleading statements about a deficient Alzheimer's drug, arguing it can sufficiently...
To view the full article, register now.